Braidwell »

Elevation Oncology shares owned by Braidwell

Quarter-by-quarter ownership of Elevation Oncology (ELEV) shares owned by Braidwell from 13F filings

Historical chart of Braidwell investment in Elevation Oncology

Tip: Access up to 7 years of quarterly data

All positions including Elevation Oncology held by Braidwell consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Elevation Oncology by Braidwell

Quarter filed Position value Share count Share price at filing
2024-03-31 $12M 2.4M 5.13

More positions owned by Braidwell

Guardant Health Note11/1 (Principal)
Bridgebio Pharma Note 2.500% 3/1 (Principal)
Exact Sciences Corp Note 0.375% 3/0 (Principal)
Novocure Note11/0 (Principal)
Apogee Therapeutics (APGE)
Nuvasive Note 0.375% 3/1 (Principal)
Neurocrine Biosciences (NBIX)
Argenx Se Sponsored Adr (ARGX)
Vaxcyte (PCVX)
Neogenomics Note 0.250% 1/1 (Principal)
Dexcom Note 0.250%11/1 (Principal)
Legend Biotech Corp Sponsored Ads (LEGN)
Insmed Note 1.750% 1/1 (Principal)
Insulet Corp Note 0.375% 9/0 (Principal)
Penumbra (PEN)

View all positions for Braidwell

Top funds holding Elevation Oncology

Farallon Capital Management
Point72 Asset Management
Tang Capital Management
Balyasny Asset Management
Aisling Capital Management
venBio Partners
Braidwell
Qiming U.S. Ventures Management
Darwin Global Management
BVF
Citadel Advisors
Vanguard Group
Artal Group
Hudson Bay Capital Management
Palo Alto Investors

View all funds holding Elevation Oncology